From Yahoo Finance: 2025-06-20 13:07:00

Shares in Verve Therapeutics surged 80.5% after Eli Lilly announced plans to acquire the company, focusing on the promising cardiovascular medicine program VERVE-102. This program targets the PCSK9 gene to lower LDL cholesterol levels, with positive phase 1b trial results showing significant reductions in LDL-C levels.

Lilly’s offer includes $10.50 per share for Verve, along with a nontradable contingent value right (CVR) that could pay up to $3 per share upon specific trial milestones. The current share price suggests a 21% chance of VERVE-102 progressing to a phase 3 trial, making the offer attractive to investors.

Before investing in Verve Therapeutics, the Motley Fool Stock Advisor team recommends considering other potential opportunities. The top 10 stocks identified by the team have historically outperformed the market significantly, offering substantial returns over the years. Don’t miss out on potentially lucrative investment options by exploring these top stock picks.

Read more: Why Lilly’s Bid for Verve Therapeutics Sent the Stock Soaring This Week